ERBB2 and breast cancer: Studies have consistently found that breast cancers in young women have more aggressive clinicopathological features with larger tumours, higher grade, more lymph node positivity, lower hormone receptor positivity, higher HER2 overexpression, and a higher proportion of triple-negative cases when compared to older women.